多西他赛注射液与顺铂联合治疗非小细胞肺癌的临床疗效  

Clinical efficacy of docetaxel combined with cis-platinum in treatment of non-small cell lung cancer

作　　者：张连国[1] 畅怡[1] 

机构地区：[1]首都医科大学宣武医院呼吸科,北京,100053

出　　处：《国际呼吸杂志》2015年第10期728-731,共4页International Journal of Respiration

摘　　要：目的：观察多西他赛注射液联合顺铂治疗非小细胞肺癌（NSCLC）的疗效和安全性。方法选取我院收治的经病理组织学确诊的Ⅲ/Ⅳ期 NSCLC 患者136例,随机分成研究组和对照组,各68例,对照组给予多西他赛单药治疗,研究组采用多西他赛联合顺铂方案治疗。评估治疗2个周期后的治疗效果及不良反应发生情况。结果治疗2个周期后,研究组总有效率高于对照组（67.6% vs 47.1%,χ2=5.892,P =0.015）,研究组患者白细胞减少、血小板降低、血清转氨酶上升的发生率明显高于对照组（χ2值分别为15.070、19.608、7.863,P 值均〈0.05）；但两组患者恶心呕吐、腹泻、脱发和乏力不良反应发生率差异无统计学意义（P 值均〉0.05）。结论多西他赛注射液联合顺铂对晚期 NSCLC 患者的治疗效果较好,血液毒性略增高,但可以耐受,可以考虑在临床应用。Objective To investigate the clinical efficacy of docetaxel combined with cis-platinum in treatment of non-small cell lung cancer （NSCLC）.Methods 136 NSCLC patients with phase Ⅲ-Ⅳdiagnosed by histopathology in our hospital were divided into research group and control group,68 cases each group.The patients in control group were treated with docetaxel while the research group was treated with docetaxel and cis-platinum.After two circle treatment,the clinical efficacy and adverse reactions were evaluated in the two groups.Results After two cycle treatment,the total efficiency rate of the research group was higher than that of the control group （67.6% vs 47.1%,χ2 = 5.892,P = 0.01 5 ）.The incidence rates of decreased neutropenia,decreased thrombocytopenia,and increased serum transaminases in the research group were higher than those in the control group （χ2 = 1 5.070,1 9.608,7.863 respectively,all P〈0.05）.There was no statistical significance in the incidence rates of nausea,vomiting, diarrhea,and hair loss between the two groups （all P 〉0.05）.Conclusions The programme of docetaxel injection combined with cisplatin is effective in the treatment of patients with advanced NSCLC,blood toxicity is slightly high but can be tolerated.It should be considered in clinical applications.

关 键 词：非小细胞肺癌 多西他赛 顺铂 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]